Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …

There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Abstract Background Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have
transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic …

MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …

Inhibition of Bruton's tyrosine kinase (BTK) has revolutionized the treatment landscape for
patients with chronic lymphocytic leukemia (CLL). By targeting this critical kinase in proximal …

Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has
elucidated a series of acquired drug-resistant BTK mutations in patients with B cell …

Covalent inhibitors of Bruton tyrosine kinase (BTK) have transformed the therapy of chronic
lymphocytic leukemia (CLL), but continuous therapy has been complicated by the …

B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies.
Activation of BCR signaling promotes the survival and proliferation of malignant B cells …